Status:

COMPLETED

Men Who Have Sex With Men (MSM) Neurocog 1&2 Study

Lead Sponsor:

St Stephens Aids Trust

Conditions:

HIV Related Neurocognitive Impairment

Eligibility:

MALE

18-49 years

Brief Summary

The treatment of HIV and the tests performed for HIV care have changed over the last 20 years but improvement of management of HIV-infected subjects is still warranted. The investigators would like to...

Detailed Description

The aim of this project is to examine neurocognitive functioning in HIV infected men who have sex with men (MSMs). We have limited our study to this group in order to better study other shared risk fa...

Eligibility Criteria

Inclusion

  • All subjects
  • 18-49 years inclusive
  • Identifying as MSM
  • Willing and able to provide written informed consent
  • Able to complete screening tools.
  • Fluent in spoken and written English
  • Patients who have given written and dated informed consent to participate in this study and to use the data.
  • Patients co-infected with chronic hepatitis B/C (diagnosed serologically at least 6 months prior to study to exclude seroconversion/recent infection) and/or currently using recreational substances including alcohol will be included in this study ("real world" data)
  • HIV-infected subjects • Known HIV of at least 6 months duration (in order to exclude symptoms associated with primary HIV infection)
  • HIV-uninfected controls
  • HIV-negative by rapid point of care test (POCT) or standard laboratory testing
  • No unprotected anal intercourse (UPAI) in last 3 months

Exclusion

  • All subjects
  • HIV or hepatitis B/C infection thought to have occurred in the last 6 months
  • Current/active central nervous system (CNS) opportunistic infections or CNS malignancies.
  • Previous cerebrovascular accidents (CVA/stroke) or history of transient ischemic attacks (TIAs).
  • Neuromuscular disease that will limit ability to perform the screening tests.
  • Patients receiving current therapy with ribavirin or interferon for hepatitis co-infection or expected to start such therapy in the coming 12 months
  • Current medical or psychiatric/psychological condition deemed significant by the investigator o (e.g. psychosis, bipolar disorder, dementia, eating disorders, severe head injury (loss of consciousness for at least an hour), current CNS opportunistic infection)

Key Trial Info

Start Date :

September 1 2011

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

237 Patients enrolled

Trial Details

Trial ID

NCT01508559

Start Date

September 1 2011

End Date

December 1 2013

Last Update

April 11 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

SSAT Clinical Trials Unit

London, United Kingdom, SW10 9NH